Equities research analysts expect Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) to announce earnings of ($0.45) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Kiniksa Pharmaceuticals’ earnings, with estimates ranging from ($0.49) to ($0.41). Kiniksa Pharmaceuticals posted earnings per share of ($0.79) in the same quarter last year, which suggests a positive year over year growth rate of 43%. The company is scheduled to announce its next quarterly earnings report on Tuesday, February 22nd.
On average, analysts expect that Kiniksa Pharmaceuticals will report full year earnings of ($2.18) per share for the current year, with EPS estimates ranging from ($2.27) to ($2.10). For the next year, analysts anticipate that the company will post earnings of ($1.63) per share, with EPS estimates ranging from ($1.85) to ($1.48). Zacks’ EPS averages are a mean average based on a survey of analysts that that provide coverage for Kiniksa Pharmaceuticals.
Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its quarterly earnings results on Monday, November 1st. The company reported ($0.44) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.65) by $0.21. The business had revenue of $12.10 million during the quarter, compared to analysts’ expectations of $9.92 million.
Institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC acquired a new stake in shares of Kiniksa Pharmaceuticals in the first quarter valued at $105,000. Dimensional Fund Advisors LP lifted its holdings in Kiniksa Pharmaceuticals by 218.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 238,047 shares of the company’s stock worth $4,406,000 after buying an additional 163,191 shares during the last quarter. Royal Bank of Canada raised its stake in Kiniksa Pharmaceuticals by 180.7% during the 1st quarter. Royal Bank of Canada now owns 5,701 shares of the company’s stock valued at $105,000 after acquiring an additional 3,670 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in Kiniksa Pharmaceuticals during the 1st quarter valued at approximately $4,068,000. Finally, Logos Global Management LP acquired a new position in Kiniksa Pharmaceuticals during the 1st quarter worth approximately $7,404,000. Hedge funds and other institutional investors own 42.04% of the company’s stock.
NASDAQ KNSA traded up $0.33 during trading hours on Friday, reaching $12.13. The company’s stock had a trading volume of 274,216 shares, compared to its average volume of 439,208. The business’s 50-day moving average is $12.29. Kiniksa Pharmaceuticals has a 1 year low of $10.30 and a 1 year high of $24.70. The stock has a market cap of $835.61 million, a P/E ratio of -4.74 and a beta of -0.07.
Kiniksa Pharmaceuticals Company Profile
Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, Vixarelimab, and KPL-404.
Read More: Bar Chart
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.